To evaluate the role of biomarkers in patients with ischemic stroke as predictors of response to systemic thrombolysis with rtPA and bleeding complications.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Multi-center, observational study.
Before administration of the drug, the patient will undergo sampling of peripheral blood for the assay of endopeptidases, haemostasis and inflammatory molecules. The same blood sample will be repeated at 24 hours and 3 months after treatment. Clinical information, laboratory and radiological (CT scan) data will also be collected. The predictive role of the markers will be analysed in relation to early neurological improvement (measured with 24-hours NIHSS) and 3 month functional outcome (measured with modified Rankin scale). Finally, the biological markers in study will be assessed as predictors of hemorrhagic transformation."
|Type||Measure||Time Frame||Safety Issue|
|Primary||Disability at 3 months as measured using the modified Rankkin scale < 2 or ? 2.|
|Secondary||Neurological score (NIHSS < or ? 8 at 48 h), ), symptomatic haemorrhage and recanalization rate, extension of the ischemic lesion (using the ASPECT Score at baseline and 24 hours).|